Estimated market cap $2.24BShares outstanding from the company’s latest SEC filing (all share classes, each priced at its own close; ADRs converted to ADS) × last close from Tiingo. Updated daily. This figure: shares as of Dec 31, 2025, last close Nov 13, 2026.65.90M ADSs, shares as of Dec 31, 2025CIK 1421876The SEC’s Central Index Key, the number it uses to identify every company and person that files.
Insider trades, 12 mo
—
No open-market trades
Congress trades, 24 mo
—
No disclosed trades
13F holders
…
Lobbying, 12 mo
—
No lobbying filings
Federal contracts, 12 mo
—
None matched
Ask your AI:
Latest 10-Q
What changed in Lakefront Biotherapeutics's latest quarterly report, compared with the one before.
We have not read a recent 10-Q for this company yet.
Insider trades
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
Loading…
13F holders
Funds that report this stock, checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Loading…
Top 10 holders.Premium lists every holder, with CSV downloads.
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
Loading…
Lobbying
What Lakefront Biotherapeutics and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
Loading…
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
13F holders, Q3 2026Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
63
22 added · 14 trimmed
Insider trades
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
No recent insider purchases or sales for this company.
13F holders
21.14M shares
63 funds report LKFT. Values checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Funds own 49% of the company, counted in US-listed ADS (Q2 2026)Fund managers with more than $100 million in US-listed stocks file a 13F each quarter. It lists their long stock positions only (shorts, options and bonds are left out) and can arrive up to 45 days after the quarter ends, so this is a snapshot of the quarter end. We add up the shares every fund reports in this class and divide by the shares outstanding. The total can pass 100%: the same shares are often reported by more than one manager (an adviser and the fund it runs), lent shares can be reported twice, and the share count can be out of date after buybacks. We divided 32.06M reported ADSs by 65.90M ADSs, from the cover page of the company’s filing as of Dec 31, 2025. An ADS stands for a fixed number of the company’s ordinary shares, so the company’s shares are converted to ADSs. 13F covers only ADSs listed in the US. Shares held at home and by funds abroad are not in it, so this figure is lower than global institutional ownership figures.
79 funds hold the stock.
Q3 2026: 32% · 5,560 of ~8,900 funds reported so farFunds have 45 days after a quarter ends to file. This quarter’s reports are still arriving, so the figure only counts the funds that have filed so far and will usually rise.
Q2 202548%
Q3 202548%
Q4 202548%
Q1 202647%
Q2 202649%
Q3 2026 (so far)32%
Q3 2026. 15 new, 22 added to, 14 trimmed, 31 exited since Q2 2026.
One of these funds reports its values in thousands of dollars; its figures are shown in dollars.
Download CSVEvery fund that holds LKFT, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Trades by members of Congress
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
No recent congressional trades for this company.
Lobbying
What Lakefront Biotherapeutics and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
No recent lobbying filings for this company.
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
Funds holding the stock
Shares they report
Funds holding the stock by quarter
Q2 2015
41
—
8.81M
$452.5M
Q3 2015
38
-3
9.05M
$368.3M
Q4 2015
44
+6
8.24M
$517.9M
Q1 2016
32
-12
8.77M
$366.6M
Q2 2016
38
+6
9.79M
$543.0M
Q3 2016
47
+9
9.71M
$627.7M
Q4 2016
52
+5
10.05M
$646.4M
Q1 2017
64
+12
10.12M
$872.4M
Q2 2017
78
+14
12.05M
$922.3M
Q3 2017
69
-9
10.09M
$1.0B
Q4 2017
77
+8
9.94M
$932.0M
Q1 2018
82
+5
8.97M
$894.3M
Q2 2018
79
-3
7.64M
$704.5M
Q3 2018
92
+13
9.53M
$1.1B
Q4 2018
85
-7
8.14M
$746.5M
Q1 2019
92
+7
8.48M
$997.9M
Q2 2019
102
+10
8.67M
$1.1B
Q3 2019
111
+9
8.46M
$1.3B
Q4 2019
137
+26
7.57M
$1.6B
Q1 2020
140
+3
7.66M
$1.5B
Q2 2020
143
+3
7.63M
$1.5B
Q3 2020
119
-24
7.42M
$1.1B
Q4 2020
116
-3
4.59M
$454.6M
Q1 2021
133
+17
6.57M
$506.0M
Q2 2021
109
-24
7.51M
$517.3M
Q3 2021
81
-28
8.55M
$449.9M
Q4 2021
83
+2
10.85M
$602.7M
Q1 2022
90
+7
12.83M
$796.2M
Q2 2022
82
-8
12.91M
$843.5M
Q3 2022
84
+2
12.92M
$551.3M
Q4 2022
75
-9
13.18M
$584.8M
Q1 2023
75
0
22.39M
$865.1M
Q2 2023
76
+1
19.71M
$801.4M
Q3 2023
73
-3
19.52M
$674.5M
Q4 2023
88
+15
19.90M
$809.0M
Q1 2024
82
-6
20.54M
$661.3M
Q2 2024
85
+3
19.94M
$494.1M
Q3 2024
79
-6
13.67M
$393.4M
Q4 2024
81
+2
31.08M
$856.9M
Q1 2025
83
+2
31.19M
$783.2M
Q2 2025
85
+2
31.78M
$889.5M
Q3 2025
93
+8
31.49M
$1.1B
Q4 2025
91
-2
31.40M
$1.0B
Q1 2026
90
-1
31.26M
$937.9M
Q2 2026
79
-11
32.06M
$960.3M
Q3 2026
63
-16
21.14M
$632.6M
Each point is a quarter-end, from Q2 2015 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.
Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.
The history follows the company's current CUSIP number (36315X101). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q2 2015) can be later than the stock's first appearance in 13F reports.
Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.
A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.